Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 34
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Hippocampus ; 34(1): 14-28, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-37950569

RESUMEN

Mnemonic discrimination (MD) may be dependent on oscillatory perforant path input frequencies to the hippocampus in a "U"-shaped fashion, where some studies show that slow and fast input frequencies support MD, while other studies show that intermediate frequencies disrupt MD. We hypothesize that pattern separation (PS) underlies frequency-dependent MD performance. We aim to study, in a computational model of the hippocampal dentate gyrus (DG), the network and cellular mechanisms governing this putative "U"-shaped PS relationship. We implemented a biophysical model of the DG that produces the hypothesized "U"-shaped input frequency-PS relationship, and its associated oscillatory electrophysiological signatures. We subsequently evaluated the network's PS ability using an adapted spatiotemporal task. We undertook systematic lesion studies to identify the network-level mechanisms driving the "U"-shaped input frequency-PS relationship. A minimal circuit of a single granule cell (GC) stimulated with oscillatory inputs was also used to study potential cellular-level mechanisms. Lesioning synapses onto GCs did not impact the "U"-shaped input frequency-PS relationship. Furthermore, GC inhibition limits PS performance for fast frequency inputs, while enhancing PS for slow frequency inputs. GC interspike interval was found to be input frequency dependent in a "U"-shaped fashion, paralleling frequency-dependent PS observed at the network level. Additionally, GCs showed an attenuated firing response for fast frequency inputs. We conclude that independent of network-level inhibition, GCs may intrinsically be capable of producing a "U"-shaped input frequency-PS relationship. GCs may preferentially decorrelate slow and fast inputs via spike timing reorganization and high frequency filtering.


Asunto(s)
Giro Dentado , Neuronas , Giro Dentado/fisiología , Neuronas/fisiología , Hipocampo/fisiología , Vía Perforante , Sinapsis/fisiología
2.
Acta Psychiatr Scand ; 150(2): 91-104, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38643982

RESUMEN

INTRODUCTION: The aim of this study was to determine whether the clinical profiles of bipolar disorder (BD) patients could be differentiated more clearly using the existing classification by diagnostic subtype or by lithium treatment responsiveness. METHODS: We included adult patients with BD-I or II (N = 477 across four sites) who were treated with lithium as their principal mood stabilizer for at least 1 year. Treatment responsiveness was defined using the dichotomized Alda score. We performed hierarchical clustering on phenotypes defined by 40 features, covering demographics, clinical course, family history, suicide behaviour, and comorbid conditions. We then measured the amount of information that inferred clusters carried about (A) BD subtype and (B) lithium responsiveness using adjusted mutual information (AMI) scores. Detailed phenotypic profiles across clusters were then evaluated with univariate comparisons. RESULTS: Two clusters were identified (n = 56 and n = 421), which captured significantly more information about lithium responsiveness (AMI range: 0.033 to 0.133) than BD subtype (AMI: 0.004 to 0.011). The smaller cluster had disproportionately more lithium responders (n = 47 [83.8%]) when compared to the larger cluster (103 [24.4%]; p = 0.006). CONCLUSIONS: Phenotypes derived from detailed clinical data may carry more information about lithium responsiveness than the current classification of diagnostic subtype. These findings support lithium responsiveness as a valid approach to stratification in clinical samples.


Asunto(s)
Trastorno Bipolar , Compuestos de Litio , Fenotipo , Humanos , Trastorno Bipolar/tratamiento farmacológico , Trastorno Bipolar/clasificación , Trastorno Bipolar/diagnóstico , Masculino , Femenino , Adulto , Persona de Mediana Edad , Análisis por Conglomerados , Compuestos de Litio/farmacología , Compuestos de Litio/uso terapéutico , Antimaníacos/uso terapéutico , Antimaníacos/farmacología
3.
Acta Psychiatr Scand ; 148(2): 133-141, 2023 08.
Artículo en Inglés | MEDLINE | ID: mdl-37190775

RESUMEN

BACKGROUND: Genetic studies of bipolar disorder (BD) have shown varied results, which is in part because of the heterogeneity of the disorder. Identifying clinical phenotypes of BD could reduce variability and benefit research. Since BD has a robust genetic component, studies can investigate clinical traits that cluster in families to identify phenotypes with a probable genetic basis. METHODS: We conducted a systematic review of the current literature on familial clinical traits of BD. Text screening and data extraction were performed independently by two reviewers, and random effects meta-analysis was used. RESULTS: Of 1117 unique records, 16 studies met inclusion criteria. These studies indicated 14 potentially familial traits of BD: age of onset (OR: 4.50; 95% CI: [3.25, 6.22]), bipolar type (OR: 2.05 [1.50, 2.79]), lithium response (OR: 3.71 [1.28, 10.82]), polarity at onset (OR: 1.17 [1.03, 1.34]), psychotic features (OR: 2.20 [1.51, 3.20]), mood-incongruent psychosis (OR: 2.52 [1.66, 3.83]), puerperal psychosis (OR: 6.54 [2.55, 16.77]), rapid cycling (OR: 4.95 [0.96, 25.40]), suicide attempt (OR: 1.04 [0.65, 1.67]), alcoholism (OR: 1.53 [1.09, 2.16]), obsessive-compulsive disorder (OR: 3.10 [1.31; 7.09]), panic disorder (OR: 2.69 [1.12; 6.48]), social anxiety disorder (OR: 1.00 [0.39, 2.55]), and specific phobia (OR: 1.94 [0.95; 3.96]). For most traits, tests of heterogeneity were significant and publication bias was likely. CONCLUSION: The results of our review and meta-analysis highlight the lack of studies investigating familial clinical traits of BD, despite the need to address heterogeneity. The large degree of variability between studies must be reduced for future research.


Asunto(s)
Trastorno Bipolar , Trastorno Obsesivo Compulsivo , Trastorno de Pánico , Trastornos Psicóticos , Humanos , Trastorno Bipolar/genética , Trastorno Bipolar/diagnóstico , Fenotipo , Trastornos Psicóticos/diagnóstico
4.
Hum Brain Mapp ; 43(1): 56-82, 2022 01.
Artículo en Inglés | MEDLINE | ID: mdl-32725849

RESUMEN

MRI-derived brain measures offer a link between genes, the environment and behavior and have been widely studied in bipolar disorder (BD). However, many neuroimaging studies of BD have been underpowered, leading to varied results and uncertainty regarding effects. The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Bipolar Disorder Working Group was formed in 2012 to empower discoveries, generate consensus findings and inform future hypothesis-driven studies of BD. Through this effort, over 150 researchers from 20 countries and 55 institutions pool data and resources to produce the largest neuroimaging studies of BD ever conducted. The ENIGMA Bipolar Disorder Working Group applies standardized processing and analysis techniques to empower large-scale meta- and mega-analyses of multimodal brain MRI and improve the replicability of studies relating brain variation to clinical and genetic data. Initial BD Working Group studies reveal widespread patterns of lower cortical thickness, subcortical volume and disrupted white matter integrity associated with BD. Findings also include mapping brain alterations of common medications like lithium, symptom patterns and clinical risk profiles and have provided further insights into the pathophysiological mechanisms of BD. Here we discuss key findings from the BD working group, its ongoing projects and future directions for large-scale, collaborative studies of mental illness.


Asunto(s)
Trastorno Bipolar , Corteza Cerebral , Imagen por Resonancia Magnética , Neuroimagen , Trastorno Bipolar/diagnóstico por imagen , Trastorno Bipolar/patología , Corteza Cerebral/diagnóstico por imagen , Corteza Cerebral/patología , Humanos , Metaanálisis como Asunto , Estudios Multicéntricos como Asunto
5.
Int J Eat Disord ; 55(3): 318-331, 2022 03.
Artículo en Inglés | MEDLINE | ID: mdl-34846763

RESUMEN

BACKGROUND: Many individuals with eating disorders remain symptomatic after a course of psychotherapy and pharmacotherapy; therefore, the development of innovative treatments is essential. METHOD: To learn more about the current evidence for treating eating disorders with stimulants, we searched for original articles and reviews published up to April 29, 2021 in PubMed and MEDLINE using the following search terms: eating disorders, anorexia, bulimia, binge eating, stimulants, amphetamine, lisdexamfetamine, methylphenidate, and phentermine. RESULTS: We propose that stimulant medications represent a novel avenue for future research based on the following: (a) the relationship between eating disorders and attention deficit/hyperactivity disorder (ADHD); (b) a neurobiological rationale; and (c) the current (but limited) evidence for stimulants as treatments for some eating disorders. Despite the possible benefits of such medications, there are also risks to consider such as medication misuse, adverse cardiovascular events, and reduction of appetite and pathological weight loss. With those risks in mind, we propose several directions for future research including: (a) randomized controlled trials to study stimulant treatment in those with bulimia nervosa (with guidance on strategies to mitigate risk); (b) examining stimulant treatment in conjunction with psychotherapy; (c) investigating the impact of stimulants on "loss of control" eating in youth with ADHD; and (d) exploring relevant neurobiological mechanisms. We also propose specific directions for exploring mediators and moderators in future clinical trials. DISCUSSION: Although this line of investigation may be viewed as controversial by some in the field, we believe that the topic warrants careful consideration for future research.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Trastorno por Atracón , Bulimia Nerviosa , Estimulantes del Sistema Nervioso Central , Adolescente , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Trastorno por Atracón/inducido químicamente , Trastorno por Atracón/tratamiento farmacológico , Bulimia Nerviosa/tratamiento farmacológico , Estimulantes del Sistema Nervioso Central/uso terapéutico , Humanos , Dimesilato de Lisdexanfetamina/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto
6.
Mol Psychiatry ; 25(9): 2130-2143, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-30171211

RESUMEN

Bipolar disorders (BDs) are among the leading causes of morbidity and disability. Objective biological markers, such as those based on brain imaging, could aid in clinical management of BD. Machine learning (ML) brings neuroimaging analyses to individual subject level and may potentially allow for their diagnostic use. However, fair and optimal application of ML requires large, multi-site datasets. We applied ML (support vector machines) to MRI data (regional cortical thickness, surface area, subcortical volumes) from 853 BD and 2167 control participants from 13 cohorts in the ENIGMA consortium. We attempted to differentiate BD from control participants, investigated different data handling strategies and studied the neuroimaging/clinical features most important for classification. Individual site accuracies ranged from 45.23% to 81.07%. Aggregate subject-level analyses yielded the highest accuracy (65.23%, 95% CI = 63.47-67.00, ROC-AUC = 71.49%, 95% CI = 69.39-73.59), followed by leave-one-site-out cross-validation (accuracy = 58.67%, 95% CI = 56.70-60.63). Meta-analysis of individual site accuracies did not provide above chance results. There was substantial agreement between the regions that contributed to identification of BD participants in the best performing site and in the aggregate dataset (Cohen's Kappa = 0.83, 95% CI = 0.829-0.831). Treatment with anticonvulsants and age were associated with greater odds of correct classification. Although short of the 80% clinically relevant accuracy threshold, the results are promising and provide a fair and realistic estimate of classification performance, which can be achieved in a large, ecologically valid, multi-site sample of BD participants based on regional neurostructural measures. Furthermore, the significant classification in different samples was based on plausible and similar neuroanatomical features. Future multi-site studies should move towards sharing of raw/voxelwise neuroimaging data.


Asunto(s)
Trastorno Bipolar , Trastorno Bipolar/diagnóstico por imagen , Encéfalo/diagnóstico por imagen , Humanos , Aprendizaje Automático , Imagen por Resonancia Magnética , Neuroimagen
7.
Int J Eat Disord ; 54(7): 1099-1105, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33825216

RESUMEN

Outpatient care (e.g., individual, group, or self-help therapies) and day treatment programs (DTPs) are common and effective treatments for adults with eating disorders. Compared to outpatient care, DTPs have additional expenses and could have unintended iatrogenic effects (e.g., may create an overly protective environment that undermines self-efficacy). However, these potential downsides may be offset if DTPs are shown to have advantages over outpatient care. To explore this question, our team conducted a scoping review that aimed to synthesize the existing body of adult eating disorder literature (a) comparing outcomes for DTPs to outpatient care, and (b) examining the use of DTPs as a higher level of care in a stepped care model. Only four studies met the predefined search criteria. The limited results suggest that the treatments have similar effects and that outpatient care is more cost-effective. Furthermore, no studies explored the use of DTPs as a higher level of care in a stepped care model (despite international guidelines recommending this approach). Given the clear dearth of literature on this clinically relevant topic, we have provided specific avenues for further research.


Asunto(s)
Trastornos de Alimentación y de la Ingestión de Alimentos , Pacientes Ambulatorios , Adulto , Atención Ambulatoria , Análisis Costo-Beneficio , Trastornos de Alimentación y de la Ingestión de Alimentos/terapia , Humanos , Resultado del Tratamiento
8.
Int J Eat Disord ; 54(5): 872-878, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33534199

RESUMEN

OBJECTIVE: This study examined the feasibility, safety, and potential efficacy of lisdexamfetamine (LDX) as a treatment for adults with bulimia nervosa (BN). METHOD: An open-label 8-week feasibility study was conducted in participants with BN. Enrollment rate, dropout rate, safety outcomes, and eating disorder symptom change were examined. RESULTS: Eighteen of 23 participants completed the study per protocol. There was no participant-initiated dropout due to adverse drug reactions and no severe and unexpected adverse drug reactions. An average increase in heart rate of 12.1 beats/min was observed. There was a mean weight reduction of 2.1 kg and one participant was withdrawn for clinically significant weight loss. In the intent-to-treat sample, there were reductions in objective binge episodes and compensatory behaviors from Baseline to Post/End-of-Treatment (mean difference = -29.83, 95% confidence interval: -43.38 to -16.27; and mean difference = -33.78, 95% confidence interval: -48.74 to -18.82, respectively). DISCUSSION: Results of this study indicate that a randomized controlled trial would be feasible with close monitoring of certain safety parameters (especially over a longer time period as long-term safety is unknown). However, the results should not be used as evidence for clinicians to prescribe LDX to individuals with BN before its efficacy and safety are properly tested. TRIAL REGISTRATION NUMBER: NCT03397446.


Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Trastorno por Atracón , Bulimia Nerviosa , Estimulantes del Sistema Nervioso Central , Adulto , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Trastorno por Atracón/tratamiento farmacológico , Bulimia Nerviosa/tratamiento farmacológico , Estimulantes del Sistema Nervioso Central/uso terapéutico , Método Doble Ciego , Estudios de Factibilidad , Humanos , Dimesilato de Lisdexanfetamina/uso terapéutico , Resultado del Tratamiento
9.
Entropy (Basel) ; 22(8)2020 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-33286629

RESUMEN

A system's heterogeneity (diversity) is the effective size of its event space, and can be quantified using the Rényi family of indices (also known as Hill numbers in ecology or Hannah-Kay indices in economics), which are indexed by an elasticity parameter q≥0. Under these indices, the heterogeneity of a composite system (the γ-heterogeneity) is decomposable into heterogeneity arising from variation within and between component subsystems (the α- and ß-heterogeneity, respectively). Since the average heterogeneity of a component subsystem should not be greater than that of the pooled system, we require that γ≥α. There exists a multiplicative decomposition for Rényi heterogeneity of composite systems with discrete event spaces, but less attention has been paid to decomposition in the continuous setting. We therefore describe multiplicative decomposition of the Rényi heterogeneity for continuous mixture distributions under parametric and non-parametric pooling assumptions. Under non-parametric pooling, the γ-heterogeneity must often be estimated numerically, but the multiplicative decomposition holds such that γ≥α for q>0. Conversely, under parametric pooling, γ-heterogeneity can be computed efficiently in closed-form, but the γ≥α condition holds reliably only at q=1. Our findings will further contribute to heterogeneity measurement in continuous systems.

10.
Entropy (Basel) ; 22(4)2020 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-33286192

RESUMEN

A discrete system's heterogeneity is measured by the Rényi heterogeneity family of indices (also known as Hill numbers or Hannah-Kay indices), whose units are the numbers equivalent. Unfortunately, numbers equivalent heterogeneity measures for non-categorical data require a priori (A) categorical partitioning and (B) pairwise distance measurement on the observable data space, thereby precluding application to problems with ill-defined categories or where semantically relevant features must be learned as abstractions from some data. We thus introduce representational Rényi heterogeneity (RRH), which transforms an observable domain onto a latent space upon which the Rényi heterogeneity is both tractable and semantically relevant. This method requires neither a priori binning nor definition of a distance function on the observable space. We show that RRH can generalize existing biodiversity and economic equality indices. Compared with existing indices on a beta-mixture distribution, we show that RRH responds more appropriately to changes in mixture component separation and weighting. Finally, we demonstrate the measurement of RRH in a set of natural images, with respect to abstract representations learned by a deep neural network. The RRH approach will further enable heterogeneity measurement in disciplines whose data do not easily conform to the assumptions of existing indices.

12.
Value Health ; 19(4): 494-504, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-27325342

RESUMEN

BACKGROUND: Mechanical circulatory support (MCS) is an option for the treatment of medically intractable end-stage heart failure. MCS therapy, however, is resource intensive. OBJECTIVE: The purpose of this report was to systematically review the MCS cost-effectiveness literature as it pertains to the treatment of adult patients in end-stage heart failure. METHODS: We conducted a systematic search and narrative review of available cost- effectiveness and cost-utility analyses of MCS in adult patients with end-stage heart failure. RESULTS: Eleven studies analyzing the cost-effectiveness or cost-utility of MCS were identified. Seven studies focused on bridge to transplantation, three studies focused on destination therapy, and one study presented analyses of both strategies. Two articles evaluated the cost-effectiveness of the HeartMate II (Thoratec Corp., Pleasanton, CA). Incremental cost-effectiveness ratios between MCS and medical management ranged between $85,025 and $200,166 for bridge to transplantation and between $87,622 and $1,257,946 for destination therapy (2012 Canadian dollars per quality-adjusted life-year). Sensitivity analyses indicated that improvements in survival and quality of life and reductions in device and initial hospital-stay costs may improve the cost-effectiveness of MCS. CONCLUSIONS: Current studies suggest that MCS is likely not cost-effective with reference to generally accepted or explicitly stated thresholds. Refined patient selection, complication rates, achieved quality of life, and device/surgical costs, however, could modify the cost-effectiveness of MCS.


Asunto(s)
Insuficiencia Cardíaca/economía , Corazón Auxiliar/economía , Análisis Costo-Beneficio , Insuficiencia Cardíaca/terapia , Trasplante de Corazón , Humanos , Calidad de Vida , Años de Vida Ajustados por Calidad de Vida , Evaluación de la Tecnología Biomédica
14.
15.
PLoS One ; 19(2): e0297708, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38306352

RESUMEN

Our objective is to propose a method capable of disentangling the magnitude, the speed, and the duration or decay rate of the time course of response to rapid antidepressant therapies. To this end, we introduce a computational model of the time course of response to a single treatment with a rapid antidepressant. Numerical simulation is used to evaluate whether model parameters can be accurately estimated from observed data. Finally, we compare our computational modelling-based approach with linear mixed effects modelling in terms of their ability to detect changes in the magnitude and time-course of response to rapid antidepressant therapies in simulated randomized trials. Simulation experiments show that the parameters of our computational model can be accurately recovered using nonlinear least squares. Parameter estimation accuracy is stable over noise levels reaching as high as 25% of the true antidepressant effect magnitude. Comparison of our approach to mixed effects modelling using simulated randomized controlled trial data demonstrates an inability of linear mixed models to disentangle effect magnitude and time course, while our computational model accurately separates these response components. Our modelling approach may accurately identify the (A) magnitude, (B) speed, and (C) durability or decay rate of response to rapid antidepressant therapies. Future studies should fit this model to data from real clinical trials, and use resulting parameter estimates to uncover predictors and causes of different elements of the temporal course of antidepressant response.


Asunto(s)
Antidepresivos , Psicoterapia , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Causalidad , Simulación por Computador , Ensayos Clínicos Controlados Aleatorios como Asunto
16.
J Affect Disord ; 351: 49-57, 2024 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-38280568

RESUMEN

INTRODUCTION: Mnemonic discrimination (MD), the ability to discriminate new stimuli from similar memories, putatively involves dentate gyrus pattern separation. Since lithium may normalize dentate gyrus functioning in lithium-responsive bipolar disorder (BD), we hypothesized that lithium treatment would be associated with better MD in lithium-responsive BD patients. METHODS: BD patients (N = 69; NResponders = 16 [23 %]) performed the Continuous Visual Memory Test (CVMT), which requires discriminating between novel and previously seen images. Before testing, all patients had prophylactic lithium responsiveness assessed over ≥1 year of therapy (with the Alda Score), although only thirty-eight patients were actively prescribed lithium at time of testing (55 %; 12/16 responders, 26/53 nonresponders). We then used computational modelling to extract patient-specific MD indices. Linear models were used to test how (A) lithium treatment, (B) lithium responsiveness via the continuous Alda score, and (C) their interaction, affected MD. RESULTS: Superior MD performance was associated with lithium treatment exclusively in lithium-responsive patients (Lithium x AldaScore ß = 0.257 [SE 0.078], p = 0.002). Consistent with prior literature, increased age was associated with worse MD (ß = -0.03 [SE 0.01], p = 0.005). LIMITATIONS: Secondary pilot analysis of retrospectively collected data in a cross-sectional design limits generalizability. CONCLUSION: Our study is the first to examine MD performance in BD. Lithium is associated with better MD performance only in lithium responders, potentially due to lithium's effects on dentate gyrus granule cell excitability. Our results may influence the development of behavioural probes for dentate gyrus neuronal hyperexcitability in BD.


Asunto(s)
Trastorno Bipolar , Litio , Humanos , Litio/uso terapéutico , Litio/farmacología , Trastorno Bipolar/tratamiento farmacológico , Proyectos Piloto , Estudios Retrospectivos , Estudios Transversales , Compuestos de Litio/uso terapéutico
17.
J Affect Disord ; 361: 189-197, 2024 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-38866253

RESUMEN

BACKGROUND: A critical challenge in the study and management of major depressive disorder (MDD) is predicting relapse. We examined the temporal correlation/coupling between depression and anxiety (called Depression-Anxiety Coupling Strength, DACS) as a predictor of relapse in patients with MDD. METHODS: We followed 97 patients with remitted MDD for an average of 394 days. Patients completed weekly self-ratings of depression and anxiety symptoms using the Quick Inventory of Depressive Symptoms (QIDS-SR) and the Generalized Anxiety Disorder 7-item scale (GAD-7). Using these longitudinal ratings we computed DACS as random slopes in a linear mixed effects model reflecting individual-specific degree of correlation between depression and anxiety across time points. We then tested DACS as an independent variable in a Cox proportional hazards model to predict relapse. RESULTS: A total of 28 patients (29 %) relapsed during the follow-up period. DACS significantly predicted confirmed relapse (hazard ratio [HR] 1.5, 95 % CI [1.01, 2.22], p = 0.043; Concordance 0.79 [SE 0.04]). This effect was independent of baseline depressive or anxiety symptoms or their average levels over the follow-up period, and was identifiable more than one month before relapse onset. LIMITATIONS: Small sample size, in a single study. Narrow phenotype and comorbidity profiles. CONCLUSIONS: DACS may offer opportunities for developing novel strategies for personalized monitoring, early detection, and intervention. Future studies should replicate our findings in larger, diverse patient populations, develop individual patient prediction models, and explore the underlying mechanisms that govern the relationship of DACS and relapse.

18.
J Card Surg ; 28(6): 670-2, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-23734563

RESUMEN

Double aortic arch is a congenital anomaly that rarely presents in adults. We describe the case of a 69-year-old male who presented with a double aortic arch, right arch dominant, left arch patent, experiencing progressive dysphagia since childhood.


Asunto(s)
Aorta Torácica/anomalías , Aorta Torácica/cirugía , Trastornos de Deglución/etiología , Procedimientos Quirúrgicos Vasculares/métodos , Anciano , Aorta Torácica/diagnóstico por imagen , Progresión de la Enfermedad , Humanos , Imagenología Tridimensional , Masculino , Tomografía Computarizada por Rayos X , Calcificación Vascular/diagnóstico por imagen , Calcificación Vascular/etiología , Calcificación Vascular/cirugía
19.
Brain Sci ; 13(11)2023 Nov 07.
Artículo en Inglés | MEDLINE | ID: mdl-38002522

RESUMEN

Subanaesthetic doses of ketamine increase γ oscillation power in neural activity measured using electroencephalography (EEG), and this effect lasts several hours after ketamine administration. The mechanisms underlying this effect are unknown. Using a computational model of the hippocampal cornu ammonis 3 (CA3) network, which is known to reproduce ketamine's acute effects on γ power, we simulated the plasticity of glutamatergic synapses in pyramidal cells to test which of the following hypotheses would best explain this sustained γ power: the direct inhibition hypothesis, which proposes that increased γ power post-ketamine administration may be caused by the potentiation of recurrent collateral synapses, and the disinhibition hypothesis, which proposes that potentiation affects synapses from both recurrent and external inputs. Our results suggest that the strengthening of external connections to pyramidal cells is able to account for the sustained γ power increase observed post-ketamine by increasing the overall activity of and synchrony between pyramidal cells. The strengthening of recurrent pyramidal weights, however, would cause an additional phase shifted voltage increase that ultimately reduces γ power due to partial cancellation. Our results therefore favor the disinhibition hypothesis for explaining sustained γ oscillations after ketamine administration.

20.
Int J Bipolar Disord ; 11(1): 25, 2023 Jul 14.
Artículo en Inglés | MEDLINE | ID: mdl-37452256

RESUMEN

BACKGROUND: The distinction between bipolar I and bipolar II disorder and its treatment implications have been a matter of ongoing debate. The aim of this study was to examine differences between patients with bipolar I and II disorders with particular emphasis on the early phases of the disorders. METHODS: 808 subjects diagnosed with bipolar I (N = 587) or bipolar II disorder (N = 221) according to DSM-IV criteria were recruited between April 1994 and March 2022 from tertiary-level mood disorder clinics. Sociodemographic and clinical variables concerning psychiatric and medical comorbidities, family history, illness course, suicidal behavior, and response to treatment were compared between the bipolar disorder types. RESULTS: Bipolar II disorder patients were more frequently women, older, married or widowed. Bipolar II disorder was associated with later "bipolar" presentation, higher age at first (hypo)mania and treatment, less frequent referral after a single episode, and more episodes before lithium treatment. A higher proportion of first-degree relatives of bipolar II patients were affected by major depression and anxiety disorders. The course of bipolar II disorder was typically characterized by depressive onset, early depressive episodes, multiple depressive recurrences, and depressive predominant polarity; less often by (hypo)mania or (hypo)mania-depression cycles at onset or during the early course. The lifetime clinical course was more frequently rated as chronic fluctuating than episodic. More patients with bipolar II disorder had a history of rapid cycling and/or high number of episodes. Mood stabilizers and antipsychotics were prescribed less frequently during the early course of bipolar II disorder, while antidepressants were more common. We found no differences in global functioning, lifetime suicide attempts, family history of suicide, age at onset of mood disorders and depressive episodes, and lithium response. CONCLUSIONS: Differences between bipolar I and II disorders are not limited to the severity of (hypo)manic syndromes but include patterns of clinical course and family history. Caution in the use of potentially mood-destabilizing agents is warranted during the early course of bipolar II disorder.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA